Menu
Date: 14-15 November 2024
Language: English
Key poins:
Welcome to the PharmaTech 2024 Conference! Prepare for an enlightening journey into cutting-edge areas such as NextGen AI, diverse clinical trials, digital accessibility, automation, data security, telemedicine, patient empowerment, and modern pharmaceutical systems.
Get ready for an agenda that transcends boundaries, fostering knowledge exchange and setting the stage for groundbreaking advancements.
The PharmaTech 2024 Conference is crafted for participants across diverse industries, including pharmaceutical executives, biotechnology leaders, healthcare innovators, clinical research professionals, data sience and analytics teams, CROs, diagnostics, solution providers, and government institutions.
Our attendees comprise Chief Data Officers, VPs, GMs, Directors, Heads, and Managers specializing in key areas such as:
This comprehensive gathering ensures insightful discussions and valuable networking opportunities across various domains.
PharmaTech 2024 Online Conference invites you to embark on a journey into the cutting-edge realms of healthcare innovation. Over two immersive days, delve into NextGen AI, clinical trial diversity, digital accessibility, automation, data security, telemedicine, patient empowerment, and modern pharmaceutical systems. This transformative event fosters collaborative ideation and drives groundbreaking advancements. Engage with industry luminaries, share insights, and shape the future of pharmaceutical innovation through thought-provoking panel discussions, interactive sessions, and engaging keynote speeches. Beyond exploration, the conference offers invaluable networking opportunities, enabling you to connect, forge partnerships, and build relationships that propel your career and impact. Whether you’re a seasoned professional, researcher, entrepreneur, or technology enthusiast, PharmaTech 2024 Online Conference promises to equip you with actionable strategies, insights, and connections to thrive in the dynamic landscape of modern healthcare.
© 2023-2024 VNA International IČO: 09236147
PharmaTech 2024 Conference
Rose-Marie Jenvert has over 20 years of experience within the medical device, pharma and biotechnology industry, and is currently working as Biocompatibility Specialist at Veranex, located in Lund Sweden. Rose-Marie is an experienced method developer of in vitro methods and holds a MSc in Molecular Biology and a PhD in Cell Biology. She has experience in performing biological evaluations of medical devices and has previously worked as study director for biocompatibility studies, setting up testing strategies and coordinating biological and chemical testing. She also has hands-on experience of testing different materials and medical devices.
Rose-Marie is actively working as an expert in ISO/TC194 WG8 with updating of the standards for skin sensitization and skin irritation (ISO 10993-10 and -23), and is also involved in the work of WG5, the standard for cytotoxicity.
Michael works as a Biocompatibility Specialist at Sonova AG, focusing on evaluating and implementing biocompatibility testing strategies for medical devices and materials. Furthermore, he has experience as a project manager in Product Stewardship, ensuring safety and regulatory compliance in the chemical sector. Since his Ph.D. in environmental toxicology, Michael consistently emphasized the development and application of innovative in vitro methods, such as the development of novel cell lines for toxicity screening. He will share practical insights and present case studies about his experience using in vitro sensitization methods for medical devices.
Jan Wirsching has many years of experience in the medical device industry working in the field of biocompatibility and material compliance, and is currently working at Maquet Cardiopulmonary GmbH, a Getinge Company. Jan holds degrees in Molecular Medicine and Toxicology. He has experience in performing biological evaluations, toxicological risk assessments and material compliance evaluations for a wide range of devices, including combination products. Jan Wirsching is actively working as an expert in the development of a guideline on characterizing and assessing nanomaterials in medical devices and in vitro diagnostics (VDI 5709).
Theme: Complexity of Combination Products: Drug Device Interactions
– What are drug device interactions and how to investigate them?
– How do drug device interactions influence the biological risk assessment?
– Case Study: Biological risk assessment of a Heparin/Albumin-coated combination product
Fabian Kriegel is currently Head of Material Development and Biocompatibility at Carl Zeiss Meditec AG, where he leads a dynamic team focused on the development of biocompatible materials, particularly for ophthalmic applications. Together with his dedicated team, Fabian ensures the seamless implementation of testing strategies in accordance with international standards for safety and efficacy. His expertise also extends to guiding projects through the complex processes of international regulatory approval, facilitating the acceptance of medical devices on a global scale.
Prior to his current role, Fabian held positions such as GLP Study Director and Genetic Toxicology Laboratory Manager in the pharmaceutical industry. Academically, Fabian has contributed to various research areas such as nanomaterial toxicity, analytical chemistry and computational biology. In addition, he is recognized as a European Registered Toxicologist and an active member of various toxicology societies.
